US 11,986,540 B2
Compositions including pafolacianine for the identification of malignant lesions
Sumith A. Kularatne, West Lafayette, IN (US)
Assigned to ON TARGET LABORATORIES, LLC, West Lafayette, IN (US)
Filed by ON TARGET LABORATORIES, LLC., West Lafayette, IN (US)
Filed on Feb. 20, 2023, as Appl. No. 18/111,704.
Claims priority of provisional application 63/312,965, filed on Feb. 23, 2022.
Prior Publication US 2023/0263911 A1, Aug. 24, 2023
Int. Cl. A61B 5/00 (2006.01); A61B 8/00 (2006.01); A61B 10/00 (2006.01); A61K 49/00 (2006.01); A61P 35/00 (2006.01)
CPC A61K 49/0032 (2013.01) [A61B 5/0071 (2013.01); A61P 35/00 (2018.01)] 15 Claims
 
1. A composition to be administered to a subject undergoing a malignant lesion resection procedure, the composition comprising a pharmaceutically effective amount between about 1 mg and about 20 mg of pafolacianine or pharmaceutically acceptable salt thereof, per about 1.6 mL volume of solution; about 3.2 mg pafolacianine or pharmaceutically acceptable salt thereof; about 14.4 mg sodium chloride; about 0.23 mg potassium phosphate monobasic; and about 1.27 mg sodium phosphate dibasic heptahydrate; and wherein the composition has a pH between about 7.1 to 7.8; wherein the pafolacianine or pharmaceutically acceptable salt thereof binds to at least one malignant lesion and emit an optical signal.